Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) saw an upside of 1.57% to $25.09 after adding $0.39 on Wednesday. The 5-day average trading volume is 738,664 shares of the company’s common stock. It has gained $25.36 in the past week and touched a new high 4 times within the past 5 days. An average of 847,401 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 815,370.
RYTM’s 1-month performance is 55.34% or $9.43 on its low of $15.61 reached on 07/11/23. The company’s shares have touched a 52-week low of $15.50 and high of $34.99, with the stock’s rally to the 52-week high happening on 01/09/23. YTD, RYTM has lost -13.85% or -$3.88 and has reached a new high 4 times. However, the current price is down -28.30% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RYTM stock investors last saw insider trading activity on Jul 26.Cramer Pamela J. (Chief Human Resources Officer) most recently sold 930 shares at $17.64 per share on Jul 26. This transaction cost the insider $16,405. Chief Accounting Officer, Roberts William T., sold 912 shares at a price of $17.50 on Mar 29. Then, on Feb 14, EVP, Head of International Mazabraud Yann sold 1,177 shares at a price of $27.03 per share. This transaction amounted to $31,814.
Valuation Metrics
RYTM stock has a beta of 1.63. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 32.25 while the price-to-book (PB) in the most recent quarter is 7.82.
Rhythm Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 6.00, with the current ratio over the same period at 6.20. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.43, while the total debt to equity was 0.43. In terms of profitability, the gross margin trailing 12 months is 88.20%. The trailing 12-month EBITDA margin is -751.98%. The firm’s gross profit as reported stood at $21.5 million against revenue of $23.64 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Rhythm Pharmaceuticals Inc.’s cash and short-term investments amounted to $137.92 million against total debt of $1.61 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 3.64% to -$46.7 million, while revenue of -$52.18 million was -11.73% off the previous quarter. Analysts expected RYTM to announce -$0.79 per share in earnings in its latest quarter, but it posted -$0.82, representing a -3.80% surprise. EBITDA for the quarter stood at more than -$46.16 million. RYTM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 127.66 million, with total debt at $1.61 million. Shareholders hold equity totaling $56.9 million.
Let’s look briefly at Rhythm Pharmaceuticals Inc. (RYTM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 89.60% to suggest the stock is trending Overbought, with historical volatility in this time period at 113.87%.
The stock’s 5-day moving average is $24.68, reflecting a +3.78% or $0.92 change from its current price. RYTM is currently trading +53.90% above its 20-day SMA, +39.83% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +54.66% and SMA200 by+12.63%.
Stochastic %K and %D was 95.12% and 92.75% and the average true range (ATR) pointed at 1.24. The RSI (14) points at 84.36%, while the 14-day stochastic is at 98.55% with the period’s ATR at 1.14. The stock’s 9-day MACD Oscillator is pointing at 2.02 and 3.92 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), BofA Securities upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for RYTM stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RYTM as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is RYTM’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $27.00 and a high of $52.00, with their median price target at $38.00. Looking at these predictions, the average price target given by analysts is for Rhythm Pharmaceuticals Inc. (RYTM) stock is $38.22.
